MARIPOSA-2 Post-progression Analysis Favors Amivantamab-Chemotherapy Combination
Erin JungmeyerCompared to chemotherapy alone, the addition of the EGFR-MET bispecific antibody significantly prolonged progression-free survival after subsequent therapy, said Dr. Ryan Gentzler during the European Lung Cancer Congress. Read more
Can Artificial Intelligence Identify Those at High Risk and Shift the Lung Cancer Screening Paradigm?
Erin JungmeyerIn a recent interview, Dr. Lecia V. Sequist, a member of the team behind the Sybil AI algorithm, discusses how technology may soon be able to predict who will develop lung cancer. Read more
FLAURA 2 Post-progression Outcomes Demonstrate Consistent Benefit, Favor Combination Arm
Erin JungmeyerDuring the European Lung Cancer Congress, Dr. Natalia Valdiviezo presented the data, which favored frontline osimertinib plus chemotherapy compared to osimertinib alone for patients with EGFR-mutated NSCLC. Read more
Antibody Drug Conjugates: Diamonds in the Rough?
Matthew Lee, MD, MPH+more
Drs. Matthew Lee, Benjamin Levy, and Balazs Halmos say several key issues need to be addressed before this class of agents can achieve wider impact. Read more
The Promise of Artificial Intelligence-Aided Pathology in Thoracic Oncology
Jan von der Thüsen, MD, PhD+more
Profs. Jan von der Thüsen and John Le Quesne say while still in the early phases, AI has the potential to bring accessible and affordable prognosis and response prediction tools to all. Read more
Regulating Artificial Intelligence
Erin JungmeyerThe US FDA’s Dr. Harpreet Singh talks with ILCN about what the increasing use of AI means for the agency as it works to ensure drugs and devices are safe and effective. Read more
Experts Debate Addition of Frontline Chemotherapy for EGFR+ NSCLC
Erin JungmeyerIn light of data from FLAURA2 and MARIPOSA, Drs. Suresh Ramalingam and Joshua Sabari weighed the pros and cons during the 2024 TTLC meeting. Read more
Should Biomarkers Be Used in the Clinical Management of ES-SCLC?
Erin JungmeyerDuring a recent debate, Drs. Anne Chiang and Stephen Liu offered differing perspectives on the feasibility of biomarker use in the small-cell lung cancer space. Read more
Food as Medicine: Research Aims to Understand the Power of Nutrition in Treating Cancer
Erin JungmeyerIn an interview with ILCN, Dr. Carolyn Presley discusses combating malnourishment in vulnerable populations and the role of the microbiome in immunotherapy efficacy. Read more
Dr. Mark Kris, who leads the IASLC Pathologic Response Project, recently provided an update on efforts to collect data to confirm whether pathologic complete response can predict long-term outcomes. Read more